首页 | 本学科首页   官方微博 | 高级检索  
     


A comparative study of adaptive dose‐finding designs for phase I oncology trials of combination therapies
Authors:Akihiro Hirakawa  Nolan A. Wages  Hiroyuki Sato  Shigeyuki Matsui
Affiliation:1. Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan;2. Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, U.S.A.;3. Biostatistics Group, Office of New Drug V, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan;4. Department of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan
Abstract:Little is known about the relative performance of competing model‐based dose‐finding methods for combination phase I trials. In this study, we focused on five model‐based dose‐finding methods that have been recently developed. We compared the recommendation rates for true maximum‐tolerated dose combinations (MTDCs) and over‐dose combinations among these methods under 16 scenarios for 3 × 3, 4 × 4, 2 × 4, and 3 × 5 dose combination matrices. We found that performance of the model‐based dose‐finding methods varied depending on (1) whether the dose combination matrix is square or not; (2) whether the true MTDCs exist within the same group along the diagonals of the dose combination matrix; and (3) the number of true MTDCs. We discuss the details of the operating characteristics and the advantages and disadvantages of the five methods compared. Copyright © 2015 John Wiley & Sons, Ltd.
Keywords:combination of two agents  comparative study  dose‐finding method  phase I trial  oncology
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号